Psilocybin for Migraine
This trial will study the effects of psilocybin on migraine headaches, specifically looking at neuroinflammatory markers.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 2 trial • 95 Patients • NCT02061293
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Does this trial have an age requirement and, if so, does it include persons over 50?
"This medical experiment is enrolling adults aged between 21 and 65."
Has recruitment begun for this particular trial yet?
"Clinicaltrials.gov suggests that patient recruitment for this medical trial is ongoing, with the initial posting on August 10th 2021 and the latest update occurring on September 2nd 2022."
How many volunteers are currently engaged in the research project?
"Affirmative, according to clinicaltrials.gov this study is actively searching for enrollees. This trial was initially posted on August 10th 2021 and the most recent update came on September 2nd 2022, with a goal of recruiting 24 patients from one medical centre."
What is the fundamental aim of this medical trial?
"The core purpose of this medical experiment, which will measure results over a period beginning two weeks before the first session and ending two months after the second one via headache diaries, is to observe any shifts in migraine frequency. Secondary objectives include transitions in peripheral oxygenation (maximum change from baseline during each test day), number of days until initial onset of migraines, and amount of 24-hour consecutive or nonconsecutive intervals free from headaches."
Has the FDA sanctioned Psilocybin for use in clinical treatments?
"As this is still in the early stages of investigation, Power's team has assigned a conservative rating of 1 to Psolocybin based on their assessment of current data relating to safety and efficacy."
What prior experiments have been done using Psilocybin as a drug?
"Currently, there are 33 studies involving psilocybin that remain active and none of them have reached phase 3. Most of these medical trials occur in Vancouver, Washington but a total of 36 sites across the USA are participating."
What requirements must be met to qualify for this trial?
"This clinical trial is open to 24 subjects aged 21-65 with migraine. To be considered, participants should not take more than two triptan medications per week for their migraines."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- VA Connecticut Healthcare System: < 24 hours
Average response time
- < 2 Days